R.JamesKlingensteinMD

PubMed

• 4 citations
  Immunologic Effector Mechanisms in Hepatitis B-Negative Chronic Active Hepatitis
  R. James Klingenstein, Jack R. Wands> ;Springer Seminars in Immunopathology. 1980 Dec 1
• Informed consent in medicine: one physician's perspective.
  Klingenstein, R. J.> ;Int J Risk Saf Med. 1992 Jan 01
• Binding of TCA to the prion protein: mechanism, implication for therapy, and application as probe for complex formation of bio-macromolecules.
  Mangels, C., Frank, A. O., Ziegler, J., Klingenstein, R., Schweimer, K., Willbold, D., Korth, C., Rösch, P., Schwarzinger, S.> ;J Biomol Struct Dyn. 2009 Oct 01
• Structure-activity relationship of tocopherol derivatives suggesting a novel non-antioxidant mechanism in antiprion potency.
  Muyrers, J., Klingenstein, R., Stitz, L., Korth, C.> ;Neurosci Lett. 2010 Jan 18
• Quinpramine is a novel compound effective in ameliorating brain autoimmune disease.
  Singh, M. P., Meyer zu Hörste, G., Hu, W., Mausberg, A. K., Cravens, P. D., Eagar, T., Löber, S., Klingenstein, R., Gmeiner, P., Korth, C., Kieseier, B. C., Stüve, O.> ;Exp Neurol. 2009 Feb 01
• A chimeric ligand approach leading to potent antiprion active acridine derivatives: design, synthesis, and biological investigations.
  Dollinger, S., Löber, S., Klingenstein, R., Korth, C., Gmeiner, P.> ;J Med Chem. 2006 Nov 2
• Similar structure-activity relationships of quinoline derivatives for antiprion and antimalarial effects.
  Klingenstein, R., Melnyk, P., Leliveld, S. R., Ryckebusch, A., Korth, C.> ;J Med Chem. 2006 Aug 24
• Saposin A mobilizes lipids from low cholesterol and high bis(monoacylglycerol)phosphate-containing membranes: patient variant Saposin A lacks lipid extraction capacity.
  Locatelli-Hoops, S., Remmel, N., Klingenstein, R., Breiden, B., Rossocha, M., Schoeniger, M., Koenigs, C., Saenger, W., Sandhoff, K.> ;J Biol Chem. 2006 Oct 27
• Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments.
  Klingenstein, R., Löber, S., Kujala, P., Godsave, S., Leliveld, S. R., Gmeiner, P., Peters, P. J., Korth, C.> ;J Neurochem. 2006 Aug
• A novel mass spectrometric assay for the cerebroside sulfate activator protein (saposin B) and arylsulfatase A.
  Norris, A. J., Whitelegge, J. P., Yaghoubian, A., Alattia, J. R., Privé, G. G., Toyokuni, T., Sun, H., Brooks, M. N., Panza, L., Matto, P., Compostella, F., Remmel, N....> ;J Lipid Res. 2005 Oct
• Phosphatidylinositol-3,5-Bisphosphate is a potent and selective inhibitor of acid sphingomyelinase.
  Kölzer, M., Arenz, C., Ferlinz, K., Werth, N., Schulze, H., Klingenstein, R., Sandhoff, K.> ;Biol Chem. 2003 Sep
• Physiological relevance of sphingolipid activator proteins in cultured human fibroblasts.
  Sadeghlar, F., Remmel, N., Breiden, B., Klingenstein, R., Schwarzmann, G., Sandhoff, K.> ;Biochimie. 2003 May 29
• The X-ray crystal structure of human beta-hexosaminidase B provides new insights into Sandhoff disease.
  Maier, T., Strater, N., Schuette, C. G., Klingenstein, R., Sandhoff, K., Saenger, W.> ;J Mol Biol. 2003 May 2
• Join now to see all